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Merkel cell carcinoma (MCC) is an aggressive primary neuroendocrine tumor of the skin,
associated with Merkel cell polyomavirus (MCPyV) in 49–89% of cases, depending on the
country of origin and the techniques of detection. The presence of MCPyV defines heteroge-
neity in MCC; MCPyV-negative cases bear a much higher mutational load, with a distinct
ultraviolet signature pattern featuring C > T transitions, as a consequence of exposure to
ultraviolet light radiation. MCC stroma has not been thoroughly studied, although MCC
patients benefit from therapy targeting PD1/PDL1.
Methods and results
In this study, using Tissue Microarrays and immunohistochemistry, we have analyzed a
series of 219 MCC cases in relation to the presence of MCPyV, and confirmed that the pres-
ence of MCPyV is associated with changes not only in the neoplastic cells, but also in the
composition of the tumor stroma. Thus, MCPyV, found in 101/176 (57,4%) analyzable
cases, exhibits changes in its tumor morphology, the density of the inflammatory infiltrate,
the phenotype of the neoplastic cells, and the cell composition of the tumor stroma. MCPyV
presence is negatively correlated with a higher level of p53 expression, and associated with
a very high frequency (86%) of HLA-I expression loss, a higher apoptotic index, and a
stroma richer in T-cells, cytotoxic T-cells, macrophages, PDL1-positive macrophages, and
B-cells.
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Conclusions
Our findings provide evidence of the basic heterogeneity of MCC, supporting the hypothesis
that the presence of MCPyV may induce a rich inflammatory response, which is at least par-
tially avoided through loss of HLA-I antigen expression. On the other hand, MCPyV-negative
cases show a much higher frequency of stronger p53 expression and, probably, p53
alterations.
Introduction
Merkel cell carcinoma (MCC) is an aggressive primary neuroendocrine tumor of the skin
[1, 2]. It is a rare neoplasm, but more than one-third of patients die of the disease and the
case-fatality rate is much higher than that of primary cutaneous melanoma [2]. Dramatic
increases in the incidence of, and mortality from, MCC have been described in several coun-
tries [3].
MCC is associated with Merkel cell polyomavirus (MCPyV) in 49–89% of cases, depending
on the country of origin and the sensitivity of the techniques used. MCPyV-negative cases, in
contrast to positive ones, bear a much higher mutational load and have a distinct ultraviolet
(UV) signature pattern, featuring C> T transitions, as a consequence of exposure to UV radia-
tion [2, 4–7]. Viral genes are known to play a role in the pathogenesis of MCC, whereby
MCPyV viruses express large, small and 57 kDa T antigens that have the potential to inhibit
retinoblastoma (RB) activity through the action of large T antigens, and to promote MCC
tumorigenesis. Small T (ST) antigen functionally inactivates TP53 by increasing the expression
of MDM2 [8].
The crucial role of cellular immunity in MCC development and progression, and the find-
ings of studies of the tumoral microenvironment provided the rationale for immunotherapy
[5].
The presence of MCPyV has been associated with changes in tumoral cells. MCPyV-nega-
tive cases carry a higher mutational load, featuring mutations involving TP53, RB and other
key genes and pathways [4–7, 9]. Relation between the presence of MCPyV and the tumor
stroma has been previously investigated, where a relation between the presence of MCPyV and
a higher number of T-cells and macrophages was found [10–13]. Previous investigators have
also demonstrated that the localization, intensity and phenotype of the T-cells are associated
with differences in survival probability [14, 15].
We report the analysis of a large series of MCC cases to assess whether the presence of
MCPyV is associated with changes not only in the neoplastic cells but also in the composition
of the tumor stroma, in an attempt to understand better the complex relationship between the
virus, tumoral cells and the tumor stroma. For this purpose we have analyzed a large series of
219 cases using tissue microarrays to improve the consistency of the multiple immunohis-
tochemistry techniques performed. Markers identifying different subpopulations of macro-
phages and lymphocytes were used, together with antibodies recognizing the presence of
MCPyV, TP53, PDL1, proliferation, apoptosis or the expression of histocompatibility antigens
by the neoplastic cells.
The data obtained were used to determine whether the presence or absence of MCPyV
identifies essential differences in the MCC pathogenesis and interaction between the stroma
and the neoplastic cells
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Material and methods
Our study involves 219 cases, collected between 1995 and 2018, that were initially diagnosed in
the following clinical centers: Fundación Jimenez Dı́az (FJD), Madrid; Hospital Virgen de la
Salud (HVS) Toledo; Complejo Hospitalario Universitario de A Coruña (CHUAC); Complejo
Hospitalario Universitario de Vigo (CHUVI); Fundación Instituto Valenciano de Oncologı́a,
Valencia; Hospital Universitario Marqués de Valdecilla (HUMV); and the Dermatohisto-
pathology Laboratory, Friedrichshafen (Germany)
Ethics declaration
All human samples used in this study were collected following the Declaration of Helsinki pro-
tocols. We kept the original records under specific restricted conditions to fulfill all current
legal requirements. All processes were approved and conducted in adherence to the specific
recommendations of the local CEIC (Comité Ético de Investigación Clı́nica, Fundación Jimé-
nez Dı́az, Madrid). (Approval code PIC075-18_FJD). Follow-up clinical data were only avail-
able for a smaller group of cases.
I confirm that all data and samples were fully anonymized before we accessed them and
that the IRB waived the requirement for informed consent.
Diagnoses were centrally reviewed and confirmed after evaluating morphology and immu-
nostaining for the following markers: CK20, CK7, CAM5.2, chromogranin A, CD56, neuron-
specific enolase, synaptophysin and TTF-1. The diagnosis was confirmed in 205 cases for
which suitable samples were available for study.
Immunohistochemistry
Histological slides were reviewed by two of the authors (CS, MP), who have experience in
MCC diagnosis, in order to choose representative areas of tumors with which to build tissue
microarrays (TMAs). Representative areas for the TMA were selected taking into account the
histological variables described in results. For each donor, two 1-mm cores of tissue were col-
lected from the paraffin block using a TMA-I manual tissue arrayer (Beecher Instruments, Sun
Prairie, WI). Cores were then arranged in five TMA paraffin blocks to construct the microar-
ray. Cores were selected from areas corresponding to both the center of the tumor and the
periphery, in order to allow a wider view of the spatial distribution of the neoplastic cells.
Whenever detected, tumor areas with inflammatory infiltrate were selected.
TMA slides were stained using the Avidin–Biotin–Immunoperoxidase technique (LSAB;
Dako, Glostrup, Denmark). Antigens were retrieved by incubating the samples with citrate
buffer at pH 6.0 and heating in an autoclave (3 min, 1.5 atm). Diaminobenzidine was used as a
chromogen and sections were counterstained with hematoxylin.
Each TMA was stained with the following antibodies:
• MCPyV: CM2B4
• P53, PD1, PDL1, FOXP3, ROR gamma, CD20, PAX5, CD4, CD8, CD3, granzyme, perforin,
active caspase 3, TIA1, CD68, CD163, CK20, CD56, synaptophysin, chromogranin, Ki 67,
HLA I, HLA II, ALK and EZH2
Appropriate positive and negative controls were performed in parallel. Details of specific
antibodies and controls are shown in S1 Table. A basic description of the flow chart in
described in the S1 Fig.
Immunostaining evaluation and scoring were performed independently by two pathologists
(CS, MP). For the markers expressed by the neoplastic cells, the results were scored according
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to the following semiquantitative criteria: negative/low: <10% positive cells; intermediate: 10–
50% positive cells; high: >50% positive cells. Quantification of the results was adapted to the
staining patterns of each antibody. Thus, Ki67 was scored only as intermediate or high (using
a threshold of 50%), while p53 and MCPyV were scored as positive or negative. MCPyV was
considered to be positive if there were>10% positive cells.
Thresholds for the stromal cells were dependent on their relative abundance, as shown in
the accompanying figures.
Statistical analysis
Continuous values were summarized as means, and maximum and minimum values. Distribu-
tions of categorical variables were summarized as absolute frequencies and percentages. Chi-
square contingency tests were performed to analyze the differences in stromal and tumoral
marker expression between the MCPyV-positive and MCPyV-negative cases.
Results
The basic clinical features of the cases included in this series are described in Table 1 Diagnos-
tic clinical data were available from 196 patients. Mean age was 78,7 yrs (range 48–105). Ratio
male/female was 81(41,3%)/115 (58,7%). It was possible to ascribe an AJCC stage (8th edition)
to 75 patients. Death attributable to the tumor was concluded for 29/64 (45.3%) patients.
Basic histological features are described in Tables 2 and 3, as estimated in whole-tumor sec-
tions. The intensity of the intratumoral inflammatory infiltrate was scored as low, intermedi-
ate, or high, in accordance with the proposal described in the ICCR Merkel Cell Carcinoma
Histopathology Reporting Guide (http://www.iccr-cancer.org/datasets/datasets-under-
consultation). A high inflammatory infiltrate was observed in 27% of cases, while an interme-
diate infiltrate was found in 33% of samples, with 40% cases exhibiting a low proportion of
inflammatory cells.
Intratumoral fibrosis was recognized by the presence of areas of intratumoral scars, pauci-
cellular areas within the tumor, which are quite frequently associated with areas of high-den-
sity lymphocytic infiltration. High-density lymphoid infiltrate and/or intratumoral fibrosis
were identified in 97/205 (47.3%) cases (S2 Fig), both features being taken as possible evidence
Table 1. Main clinical features.
Age (median) 78.7 yrs (range 48–105)
Sex (N:196) 81 Male (41,3%) /115 Female (58,7%)
Site (N:168) Head and neck: 76 (45,2%)
Trunk: 7 (4,2%)
Upper extremities: 23 (13,7%)
Lower extremities: 59 (35,2%)
Lymph node: 3 (1,7%)




Immunosuppression: HIV, autoimmune disease, transplant, cancer (N:97) 18 (18,5%)
Death by the tumour�: (N:64) 29 (45,3%)
� Full clinical diagnostic and follow-up information was only available in 64 cases
https://doi.org/10.1371/journal.pone.0232517.t001
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of tumor regression. In this series, there was no relation between the intensity of the lymphoid
infiltrate and the survival probability.
The main IHC markers for the neoplastic cells, measured in TMAs, are listed in
Table 4. MCPyV positivity was found in 101 of the 176 (57.3%) cases considered to be ana-
lyzable. Strong uniform p53 expression by the neoplastic cells was observed in 40/180
(22.2%) cases. PAX5 was found to be expressed by the neoplastic cells in 59% of the sam-
ples. Most cases exhibited ALK expression, with only 15/174 (8.6%) cases recorded as neg-
ative. HLA-I expression was partially or completely lost in most cases, with only 49/180
(27.2%) cases showing homogeneous staining. HLA-II expression was only found in 2/180
(1.1%) cases. Active caspase 3 was used to measure the level of apoptosis, with only 4% of
cases yielding negative results. PDL1 expression by the neoplastic cells was found in 22/
179 (12.3%) cases. CD56 expression was found in the tumoral cells of 144/169 (85.2%)
cases.
The cell composition of the neoplastic stroma was analyzed, taking into account the pres-
ence and phenotype of lymphocytes, myeloid cells and macrophages (Table 5)
Specific thresholds were used for each marker depending on the relative presence. A con-
spicuous T-cell infiltrate was seen in roughly two-thirds of the cases, with frequent cytotoxic
T-cells, defined by the expression of TIA1, perforin or granzyme B. The vast majority of cases
featured some macrophages in the stroma (CD68 or CD163), with roughly half of the cases
having PDL1-positive macrophages. CD3+ CD4+ T-cells were also present in a significant
number of cases (97/181) (53.6%), and B-cells (identified with CD20) were present in two-
thirds of the cases. Presence of specific subpopulations of T-cells were also identified: FOXP3
regulatory T-cells were present in 85/177 (48.0%) cases, while TH17 T-cells recognized by the
antibody ROR-GT were found in 27/180 (15.0%) cases.
Relationship with MCPyV expression
Histological and immunohistochemical markers in MCPyV-positive and MCPyV-negative
cases were compared. The significant findings are presented in Table 6 and illustrated in Figs 1
and 2. The most important of these are described below.
MCPyV-positive cases showed changes in morphology, the density of the inflammatory
infiltrate, the phenotype of the neoplastic cells, and the cell composition of the tumor stroma.
Specifically, MCPyV-positive cases had, among other things, a much lower frequency of higher
p53 expression (4% vs. 46% cases), a higher frequency of ALK expression (83% vs. 49%), a
more frequent loss of HLA-I expression (86% vs. 58%), a higher apoptotic index with more
Table 3. Basic histological variables.
VARIABLES PRESENCE





Table 2. Basic histological variables.
Pattern (N:144) Nodular 112 (77.8%) Trabecular 19 (13.2%) Mixed 13 (9%)
Lymphocytic infiltrate (N:134) Low 54 (40.3%) Intermediate 44 (32.8%) High 36 (26.9%)
Level of infiltration (N:76) Dermis 22 (28.9%) Hypodermis 44 (57.9%) Muscle 10 (13.2%)
https://doi.org/10.1371/journal.pone.0232517.t002
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intense expression of active caspase 3) (79% vs. 45%), and a stroma richer in T-cells, cytotoxic
T-cells, macrophages, PDL1-positive macrophages and B-cells (Table 6).
Discussion
MCC was originally described as a primary cutaneous neuroendocrine small-cell cancer with
aggressive behavior [1]. It was subsequently noted that most MCC cases carried MCPyV, the
frequency varying between 49% and 89%, depending on the extent of exposure to UV radia-
tion and the detection technique [16].
Table 5. Main IHC markers for the stromal cells.
MARKERS NEGATIVE/LOW INTERMEDIATE POSITIVE
MACROPHAGES CD68 (N: 178) 5 (2.8%) 124 (69.7%) 49 (27.5%)
CD163 (N:180) 12 (6.7%) 99 (55%) 69 (38.3%)
PDL1 (N:176) 83 (47.2%) NA 93 (52.8%)
CYTOTOXIC Granzyme (N:178) 82 (46.1%) 73 (41%) 23 (12.9%)
Perforin (N:110) 91 (82.7%) 3 (2.7%) 16 (14.6%)
TIA1 (N:177) 41 (23.2%) 93 (52.5%) 43 (24.3%)
T-CELLS CD3 (N:175) 64 (36.6%) 60 (34.3%) 51 (29.1%)
CD4 (N:181) 84 (46.4%) NA 97 (53.6%)
CD8 (N:180) 66 (36.7%) NA 114 (63.3%)
FOXP3 (N:177) 92(52%) 9 (5.1%) 76 (42.9%)
ROR gamma (N:180) 153 (85%) 4 (2.2%) 23 (12.8%)
PD1 (N:176) 95 (54%) NA 81(46%)
B-CELLS CD20 (N:177) 128 (72.3%) NA 49 (27.7%)
NA: Not available. Most markers were read as Negative-Low/Intermediate/Positive. A few markers were just dichotomised into Negative/Positive (PDL1 stroma, CD4,
CD8, CD20, PD1)
https://doi.org/10.1371/journal.pone.0232517.t005
Table 4. Main IHC markers for the neoplastic cells.
MARKERS NEGATIVE/LOW INTERMEDIATE POSITIVE
Cytokeratin CK20 (N:182) 27 (14,8%) NA 155 (85.2%)
Neuroendocrine markers Synaptophysin (N:164) 9 (5.5%) 31 (18.9%) 124(75.6%)
Chromogranin (N:184) 20 (10.9%) 49 (26.6%) 115(62.5%)
CD56 (N: 175) 25 (14.3%) 41 (23.4%) 109 (62.3%)
MCPyV MCPyV (N:176) 75 (43%) NA 101 (57%)
P53 P53 (N:180) 140 (77.8%) NA 40 (22.2%)
Oncogenes ALK (N:174) 15 (8.6%) 39 (22.4%) 120 (69%)
EZH2 (N:164) 4 (2.3%) 12 (6.9%) 158 (90.8%)
Proliferation Ki67 (N:138) NA 103 (74.6%) 35 (25.4%)
Apoptosis Active Caspase 3 (N:137) 6 (4.3%) 41 (30%) 90 (65.7%)
Immune regulation HLA-I (N:180) 78 (43.3%) 53 (29.4%) 49 (27.3%)
HLA-II (N:180) 178 (98.8%) 1 (0.6%) 1 (0.6%)
PDL1 tumor (N: 179) 157 (87.7%) NA 22 (12.3%)
PAX5 PAX 5 (183) 75 (41%) NA 108 (59%)
NA: Not available. Most markers were read as Negative-Low/Intermediate/Positive. A few markers were just dichotomized into Negative/Positive (MCPyV, P53, PDL1),
or Intermediate/Positive (Ki67)
https://doi.org/10.1371/journal.pone.0232517.t004
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Table 6. Comparison between MCPyV-positive and negative cases.
MARKERS TOTAL MCPyV POSITIVE MCPyV NEGATIVE SIGNIFICANCE
Morphology Combined histology Pure MCC N:124 Combined: 19 (15.3%) 2 (2.9%) 17 (31.8%) P<0.001, Chi2:19.25
Pure MCC: 105 (84.7%) 68 (97.1%) 37 (68.5%)
Lymphoid infiltration N:127 Low: 53(41.7%) 23(32.4%) 30(53.6%) P:0.013, Chi2: 8.64
Intermediate: 41(32.3%) 23(32.3%) 18(32.1%)
High: 33 (26%) 25(35.2%) 8 (14.3%)
UIceration N:124 Presence: 26 (21%) 4 (5.9%) 22 (39.3%) P<0.001, Chi2:20.68
Absence: 98 (79%) 64(94.1%) 34 (60.7%)
Elastosis N:118 Presence 65 (55.1%) 27(41.5%) 38 (71.7%) P:0.001, Chi2: 10.73
Absence: 53 (44.9%) 38(58.5%) 15 (28.3%)
IHC neoplastic cells CK20 N:172 Positive: 146(84.8%) 92(93.9%) 54(73%) P<0.001, Chi2: 14.36
Negative/Low: 26 (15.1%) 6 (6.1%) 20(27.0%)
P53 N:171 High: 38(22.2%) 4(4.1%) 34(45.9%) P<0.001, Chi2: 42.48
Negative/Low: 133(77.8%) 93(95.9%) 40(54.0%)
Ki67 N:132 High: 35(26.5%) 12(15.4%) 23(42.6%) P<0.001, Chi2: 12.12
Intermediate: 97 (73.5%) 66(84.6%) 31(57.4%)
Chromogranin N:171 High: 105(61.4%) 71(71.7%) 34(47.2%) P<0.001, Chi2: 18.32
Negative/Low: 19 (11.1%) 3 (3%) 16(22.2%)
Intermediate: 47 (27.5%) 25(25.2%) 22(30.6%)
Synaptophysin N:152 High: 118(77.6%) 80(88.9%) 38(61.3%) P<0.001, Chi2: 16.15
Negative/Low: 6 (4%) 2(2.2%) 4(6.4%)
Intermediate: 28 (18.4%) 8 (8.9%) 20(32.3%)
ALK N:169 High: 113(68.5%) 79(83.2%) 34(48.6%) P<0.001; Chi2: 24.96
Negative/Low: 15 (9.1%) 2 (2.1%) 13(18.6%)
Intermediate 37(22.4%) 14(14.7%) 23(32.9%)
EZH2 N:166 High: 151(91%) 90(95.7%) 61(84.7%) P:0.014; Chi2: 8.47
Negative/Low: 3 (1.8%) 2 (2.1%) 1(1.4%)
Intermediate: 12 (7.2%) 2 (2.1%) 10(13.9%)
HLA-I N:166 High: 44(26.2%) 13(13.7%) 31(42.5%) p<0.001; Chi2: 25.04
Negative/Low: 72(42.9%) 55(57.9%) 17(23.3%)
Intermediate: 52(30.9%) 27(28.4%) 25(34.2%)
Active Caspase 3 N:127 High: 82(64.6%) 57(79.2%) 25(45.4%) P<0.001; Chi2: 18.62
Negative/Low: 6(4.7%) 0 (0.0%) 6(10.9%)
Intermediate: 39(30.7%) 15(20.8%) 24(43.6%)
PAX5 N:171 High: 103(60.2%) 74(75.5%) 29(39.7%) P<0.001; Chi2: 22.37
Negative/Low: 68(39.8%) 24(24.5%) 44(60.3%)
CD56 N:169 High: 105 (62.1%) 64(66.7%) 41(56.2%) P:0.025; Chi2: 7.36
Negative/Low: 25 (14.8%) 8(8.3%) 17(23.3%)
Intermediate: 39 (23.1%) 24(25%) 15(20.6%)
IHC Tumour stroma CD3 N:169 High: 48 (28.4%) 39(40.6%) 9(12.3%) P<0.001; Chi2: 16.33
Negative/low: 62 (36.7%) 29(30.2%) 33(45.2%)
Intermediate: 59 (34.9%) 28(29.2%) 31(42.5%)
CD4 N:172 High: 93 (54.1%) 63(64.3%) 30(40.5%) P:0.002; Chi2: 9.57
Negative/low: 79(45.9%) 35(25.7%) 44(59.5%)
CD20 N:169 High: 46(27.2%) 38(39.6%) 8(11%) P<0.001; Chi2: 17.15
Low: 123(72.8%) 58(60.4%) 65(89%)
FOXP3 N:165 High: 73 (44.2%) 54(56.8%) 19(27.1%) P:0.001; Chi2: 14.46
Negative/Low 87 (52.7%) 39(41%) 48(68.6%)
Intermediate: 5 (3%) 2(2.1%) 3(4.3%)
ROR gamma N:168 High: 22(13.1%) 15(15.5%) 7(9.9%) P:0.04; Chi2: 6.4533
Negative/Low: 142(84.5%) 82(84.5%) 60(84.5%)
Intermediate: 4(2.4%) 0 (0%) 4(2.4%)
PD1 N:167 High: 78(46.7%) 52(55.9%) 41(44.1%) P:0.008; Chi2: 7.15
Negative/Low: 89(53.3%) 26(35.1%) 48(64.9%)
(Continued)
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In this study, we have detected the presence of MCPyV using the antibody CM2B4, as vali-
dated by Moshiri et al [17]. The frequency of MCPyV positivity is consistent with those noted
in other studies performed in Southern Europe employing a combination of PCR and IHC [5,
17]. The results confirm that TMAs can be used in the analysis of complex solid tumors; thus,
the use of antibodies recognizing diverse cell types can be associated with multiple markers
recognizing the expression of genes involved in MCC pathogenesis.
Molecular studies have previously shown that MCPyV-positive cases exhibit a different
spectrum of molecular alterations [4, 5, 18, 19], although these studies have generally been of
series with relatively small numbers of cases. Our study shows that MCPyV-positive and
MCPyV-negative cases differ with respect to most of the markers analyzed here, particularly
the higher level of p53 expression revealed by IHC (46% vs. 4%), but also the expression of
multiple markers. The phenotype of MCPyV-positive cases is characterized by more frequent
CK20 expression, a very low frequency of p53 expression, a lower level of Ki67 expression,
Table 6. (Continued)
MARKERS TOTAL MCPyV POSITIVE MCPyV NEGATIVE SIGNIFICANCE
CD8 N: 169 High: 108(63.9%) 67(69.8%) 29(30.2%) P:0.068; Chi2: 3.34
Negative/Low: 61(36.1%) 29(30.2%) 32(43.8%)
CD68 N:169 High: 46(27.2%) 36(37.1%) 10(13.9%) P:0.001; Chi2: 18.62
Negative/Low: 5(3%) 1 (1%) 4 (5.6%)
Intermediate: 118(69.8%) 60(61.9%) 58(80.9%)
Granzyme B N:169 High: 23 (13.6%) 18(18.6%) 5(6.9%) P<0.001, Chi2:15.24
Negative/Low: 77(45.6%) 32(33%) 45(62.5%)
Intermediate: 69(40.8%) 47(48.4%) 22(30.6%)
Perforin N:101 High: 15 (14.8%) 13(22%) 2(4.8%) P:0.014, Chi2:8.56
Negative/Low: 83(82.2%) 43(72.9%) 40(95.2%)
Intermediate: 3(3%) 3(5%) 0 (0%)
TIA1 N:169 High: 39(23.1%) 31(32%) 8(11.1%) P<0.001; Chi2: 17.04
Negative/Low: 39(23.1%) 13(13.4%) 26(36.1%)
Intermediate 91(53.8%) 53(54.6%) 38(52.8%)
PDL1 stroma N: 167 High: 87(52.1%) 60(63.8%) 27(37%) P:0.001; Chi2: 11.86
Negative/Low: 80(47.9%) 34(36.2%) 46(63%)
https://doi.org/10.1371/journal.pone.0232517.t006
Fig 1. MCC-neoplastic cells.
https://doi.org/10.1371/journal.pone.0232517.g001
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more frequent neuroendocrine differentiation, and more intense ALK and EZH2 expression.
These findings confirm and build on previous observations. It is of particular note the high fre-
quency of HLA-I loss found in this series, a finding that is particularly striking in MCPyV-pos-
itive cases (86% vs. 43% in the negative cases). These data are in line with previously published
data showing that HLA-I loss is observed in a majority of MCC samples, and caused by epige-
netic silencing of the antigen presentation machinery [20]. This phenomenon is thought to
underlie the regression of metastatic MCC following transfer of polyomavirus-specific T-cells
and therapies capable of re-inducing HLA class-I [21, 22].
In this context, it is significant that the expression of active caspase 3 demonstrates that
MCPyV-positive cases contain a higher proportion of apoptotic cells than negative cases. The
apoptotic index could be interpreted, in this situation, as a surrogate marker of the intensity of
the antitumoral immune response.
This study has also included a set or markers that identify some key components of the
tumor microenvironment. Bearing in mind the possibilities that immunotherapy has opened
up for the treatment of MCC cases, we consider it of particular significance that our study also
shows the presence of MCPyV to be associated with differences in the tumor stroma. MCPyV-
Fig 2. Differences in the expression of the most significant markers. A: Neoplastic cells: Caspase 3, HLA-I, ALK, KI67, P53. B: Tumor stroma: PDL1, TIA1, CD3,
CD68, ROR GAMMA, CD20.
https://doi.org/10.1371/journal.pone.0232517.g002
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positive cases are characterized by differences in the proportion of specific T-cell subpopula-
tions and macrophages. Specifically, they have a higher proportion of CD3+, CD4+, FOXP3+,
RORgamma+, PD1+ T-cells, and a more cytotoxic phenotype (increase in TIA1, granzyme B,
perforin), an increased presence of CD20+, and a higher proportion of CD68+ macrophages
(but not of CD163) and PDL1-positive macrophages. These results confirm previously pub-
lished data [10–15] and extend these observations to the identification of specific T-cell, mac-
rophage and B-cell subsets whose presence is associated with MCPyV. Our data concerning
PDL1 expression are largely consistent with those recently published by Walsh and coworkers
[11], i.e., PDL1 is mainly expressed by peritumoral macrophages rather than neoplastic cells
[13, 23]: in our series, PDL1 expression by neoplastic cells was observed in just 22/179 (12%)
cases, a slightly lower proportion than that found by Wehkamp et al and Benigni et al [24, 25].
Our results are basically consistent with those of Miller et al, who showed that MCPyV-positive
tumors had a strikingly more clonal intratumoral TCR repertoire than MCPyV-negative
tumors [26].
These findings could give support to the interpretation that the presence of MCPyV may
induce a rich inflammatory response, which is at least partially evaded through loss of HLA-I
antigen expression. The increased level of somatic mutations, as found in the MCPyV-negative
cases, could also induce an inflammatory response, albeit with a lower intensity, that may also
explain the relatively lower frequency of the loss of HLA-I expression.
The use of tissue microarrays have obvious limitations in the semi-quantitative assessment
of different cellular populations; but at the same time improves the reproducibility of the
results since basic experimental conditions are much more similar [27]. Data here generated
are consistent with previously published data, which is supporting the experimental approach;
while at the same time expand the knowledge on the interaction between the MCC cells and
the stromal cell subpopulations.
Overall, our study provides strong evidence that MCCs carrying MCPyV have very differ-
ent features from those of MCPyV-negative cases, and extends previous observations about
mutational load [4–7, 9] to the field of stroma cellular composition, thereby implying that
MCPyV-positive and MCPyV-negative cases are different tumors in terms of their molecular
pathogenesis and prognosis.
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